Amneal Pharmaceuticals saw a notable surge in its stock price following a key FDA approval.
Shares of Amneal Pharmaceuticals, Inc. Class A Common Stock (NASDAQ:AMRX) went up yesterday, gaining 3.69% to close at CA$20.50. This increase was mainly driven by the announcement of FDA approval for its generic lanreotide injection, marking a significant milestone for the company.
Advertisement
Amneal Pharmaceuticals, Inc. Class A Common Stock
AMRX.US
AMRX.US
Amneal Pharmaceuticals, Inc. Class A Common Stock
WealthAwesomeMarket cap
$7.14B
P/E
41.0x
52W high
$21.18
52W low
$9.56
1W change
+1.69%
Beta
1.24
Analyst Price Targets
Based on 4 analysts covering AMRX · as of Sep 24, 2026
Wall Street analysts forecast AMRX stock price to rise 10.8% over the next 12 months.
Consensus
Buy4.25 / 5.00
Avg. Target
C$22.71
+10.8% Upside
Previously C$22.00 on Sep 21, 2026
Current Price
C$20.50
Last close
Analyst Breakdown (4 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMRX's historical volatility
30-Day Vol
42.5%
Annualized
90-Day Vol
38.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$24.51
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$21.76 | C$18.79 – C$25.19 |
| 60 trading days | C$23.09 | C$18.77 – C$28.41 |
| 90 trading days | C$24.51 | C$19.01 – C$31.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The FDA's approval of Amneal's generic lanreotide injection positions the company to capture a share of a lucrative market, potentially boosting its revenue and profitability in the near future.
3.69% Increase in Stock Price
Amneal's stock has reached a new 52-week high, reflecting strong investor confidence following the FDA approval announcement.
Bull case
With the FDA approval, Amneal is entering a market where the reference drug generated nearly $1 billion in annual sales, presenting a strong growth opportunity. The company's stock has also shown resilience, increasing by 62% year-to-date, which indicates positive market sentiment.
Bear case
Despite the good news, Amneal's stock remains vulnerable to market volatility. Any delays or issues in rolling out the product could shake investor confidence. Additionally, the pharmaceutical sector is competitive, and maintaining market share will require ongoing innovation and effective marketing.
Advertisement
FDA Approval Sparks Investor Optimism
The FDA's approval of Amneal's generic lanreotide injection is a significant achievement for the company, allowing it to enter a market where the reference drug, SOMATULINE Depot, previously generated $983 million in annual sales. This approval not only validates Amneal's product development efforts but also enhances its competitive positioning in the pharmaceutical landscape.
Strong Year-to-Date Performance
Amneal's stock has surged by 62% since the beginning of the year, reflecting a robust recovery and investor confidence in its growth trajectory. The recent approval is expected to further bolster this momentum, as the company anticipates increased revenue from its new product offerings.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
